Webcast Alert: Aastrom Announces Its Third Quarter Investor Conference Call
May 03 2007 - 8:00AM
Business Wire
Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following
Webcast: What: Aastrom Biosciences, Inc. 3rd Quarter Fiscal Year
2007 Investor Conference Call When: Tuesday, May 8, 2007 @ 9:00 am
(EDT) Where: http://www.vcall.com/IC/CEPage.asp?ID=115723 How: �
For live Internet access, simply log on to the web at the address
above. � For phone access, interested parties should call toll-free
(877) 407-9205 before the start of the call to register and
identify themselves as registrants of the �Aastrom Conference
Call�. Any registered caller on the toll-free line may ask for call
operator for directions to be placed in the queue for the Question
& Answer session. If calling from outside the U.S., please use
the international phone number (201) 689-8054. � To download the
podcast, simply log on to the web at the address above. Contact:
Investor Relations Department, (734) 930-5777 or mail@aastrom.com
If you are unable to participate during the live call, the webcast
will be available for replay at http://www.investorcalendar.com/
for 60 days. Through May 18, 2007, the audio replay of the
call�will be available by dialing toll-free�(877) 660-6853, or from
outside the U.S. (201) 612-7415. When prompted on the phone, the
Account # is: 286, and the Conference ID# is: 237442. Aastrom is a
regenerative medicine company developing autologous cell products
for the repair or regeneration of multiple human tissues, based on
its proprietary Tissue Repair Cell (TRC) Technology. Aastrom's
TRC-based products are a unique cell mixture of stem and progenitor
cells, produced from a small amount of bone marrow taken from the
patient. TRC-based products have been used in over 250 patients,
and are currently in clinical trials for bone regeneration
(osteonecrosis of the femoral head, long bone fractures and spine
fusion) and vascular regeneration (critical limb ischemia)
applications. Aastrom has reported positive interim clinical trial
results suggesting both the clinical safety and the ability of TRC
products to promote healing in bone regeneration applications. The
Company is also developing programs for TRC-based therapies to
address cardiac and neural regeneration indications. TRCs have
received Orphan Drug Designation from the FDA for use in the
treatment of osteonecrosis of the femoral head and the treatment of
dilated cardiomyopathy, a severe chronic disease of the heart. For
more information, visit Aastrom�s website at www.aastrom.com.
(astmc)
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024